DK2422789T3 - Injicerbar sammensætning omfattende natriumdeoxycholat - Google Patents
Injicerbar sammensætning omfattende natriumdeoxycholat Download PDFInfo
- Publication number
- DK2422789T3 DK2422789T3 DK11166225.0T DK11166225T DK2422789T3 DK 2422789 T3 DK2422789 T3 DK 2422789T3 DK 11166225 T DK11166225 T DK 11166225T DK 2422789 T3 DK2422789 T3 DK 2422789T3
- Authority
- DK
- Denmark
- Prior art keywords
- fat
- phosphatidylcholine
- sodium deoxycholate
- deoxycholate
- pbf
- Prior art date
Links
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 title claims description 59
- 229960003964 deoxycholic acid Drugs 0.000 title claims description 34
- 239000007972 injectable composition Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000001356 surgical procedure Methods 0.000 claims abstract description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 210000000744 eyelid Anatomy 0.000 claims abstract description 10
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims abstract description 7
- 208000006132 lipodystrophy Diseases 0.000 claims abstract description 7
- 208000035484 Cellulite Diseases 0.000 claims abstract description 4
- 206010049752 Peau d'orange Diseases 0.000 claims abstract description 4
- 230000036232 cellulite Effects 0.000 claims abstract description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 66
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 24
- 206010024612 Lipoma Diseases 0.000 claims description 12
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 5
- 102000001974 Hyaluronidases Human genes 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 229960002773 hyaluronidase Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 230000035515 penetration Effects 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000002270 dispersing agent Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 244000309464 bull Species 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 abstract description 50
- 238000007443 liposuction Methods 0.000 abstract description 23
- 230000035508 accumulation Effects 0.000 abstract description 14
- 238000009825 accumulation Methods 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 239000006185 dispersion Substances 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 4
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 30
- 229940009976 deoxycholate Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000009472 formulation Methods 0.000 description 22
- 210000000170 cell membrane Anatomy 0.000 description 21
- 239000003833 bile salt Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 230000007928 solubilization Effects 0.000 description 15
- 238000005063 solubilization Methods 0.000 description 15
- 210000001789 adipocyte Anatomy 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 13
- 229940093761 bile salts Drugs 0.000 description 12
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 239000000232 Lipid Bilayer Substances 0.000 description 10
- 239000000693 micelle Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 8
- 230000006037 cell lysis Effects 0.000 description 8
- 229960002378 oftasceine Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 206010062315 Lipohypertrophy Diseases 0.000 description 5
- 231100000070 MTS assay Toxicity 0.000 description 5
- 238000000719 MTS assay Methods 0.000 description 5
- 239000008135 aqueous vehicle Substances 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000001236 detergent effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000416 LDH assay Toxicity 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010048211 Xanthelasma Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940124327 inhalation anaesthetic agent Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008349 purified phosphatidyl choline Substances 0.000 description 2
- 239000001057 purple pigment Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- -1 tetrazolium compound Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035021 Pigmentation changes Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000405965 Scomberomorus brasiliensis Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 102000005311 colipase Human genes 0.000 description 1
- 108020002632 colipase Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 238000007632 sclerotherapy Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
- Medicinal Preparation (AREA)
- Edible Oils And Fats (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Claims (12)
1. Kosmetisk fremgangsmåde til ikke-kirurgisk fjernelse af lokaliseret fedtopbygning omfattende indgivelse ved injektion af en sammensætning bestående i det væsentlige af natriumdeoxycholat og ét eller flere farmaceutisk acceptable excipienser, hvor sammensætningen er fri for phosphatidylcholin.
2. Fremgangsmåde ifølge krav 1, hvor sammensætningen omfatter natriumdeoxycholat i en koncentration på mellem 0,001% og 5%.
3. Fremgangsmåde ifølge krav 2, hvor sammensætningen omfatter natriumdeoxycholat i en koncentration på mellem 0,001% og 2,5%, såsom 2,5%.
4. Fremgangsmåde ifølge krav 3, hvor sammensætningen omfatter natriumdeoxycholat i en koncentration på mellem 0,001% og 1%, såsom 1%.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor den farmaceutisk acceptable excipiens er ikke-toksisk.
6. Fremgangsmåde ifølge krav 1, hvor et af de ene eller flere farmaceutisk acceptable excipienser er benzylalkohol og/eller vand.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor sammensætningen endvidere omfatter én eller flere yderligere ingredienser valgt blandt dispersionsmidler, penetrationsforstærkere og konserveringsmidler.
8. Fremgangsmåde ifølge krav 7, hvor den ene eller flere yderligere ingredienser er valgt fra en penetrationsforstærker og et dispersionsmiddel.
9. Fremgangsmåde ifølge krav 8, hvor dispersionsmidlet er valgt blandt hyaluroni-dase og kollagenase.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor sammensætningen indgives direkte i fedtvæv.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10, hvor den lokaliserede fedtopbygning er i et menneske.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11, hvor den lokaliserede fedtopbygning er fedthernie i nedre øjenlåg; fedtopbygning i taljen eller hoften xante-lasma; lipomas; lipodystrofi, herunder "tyrenakke"-lipodystrofi; og fedtaflejringer forbundet med cellulite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57287904P | 2004-05-19 | 2004-05-19 | |
EP05722895A EP1758590B1 (en) | 2004-05-19 | 2005-02-08 | Use of a detergent for the non-surgical removal of fat |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2422789T3 true DK2422789T3 (da) | 2018-02-26 |
Family
ID=34961536
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11166225.0T DK2422789T3 (da) | 2004-05-19 | 2005-02-08 | Injicerbar sammensætning omfattende natriumdeoxycholat |
DK05722895.9T DK1758590T3 (da) | 2004-05-19 | 2005-02-08 | Anvendelse af et detergent til ikke-kirurgisk fjernelse af fedt |
DK05751896.1T DK1748780T3 (da) | 2004-05-19 | 2005-05-19 | Fremgangsmåder og relaterede sammensætninger til mindskelse af fedt |
DK20166727.6T DK3692995T3 (da) | 2004-05-19 | 2005-05-19 | Deoxycholat til reduktion af fedt |
DK11166230.0T DK2380576T3 (da) | 2004-05-19 | 2005-05-19 | Anvendelse af natriumdeoxycholat til ikke-kirurgisk fjernelse af fedt |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05722895.9T DK1758590T3 (da) | 2004-05-19 | 2005-02-08 | Anvendelse af et detergent til ikke-kirurgisk fjernelse af fedt |
DK05751896.1T DK1748780T3 (da) | 2004-05-19 | 2005-05-19 | Fremgangsmåder og relaterede sammensætninger til mindskelse af fedt |
DK20166727.6T DK3692995T3 (da) | 2004-05-19 | 2005-05-19 | Deoxycholat til reduktion af fedt |
DK11166230.0T DK2380576T3 (da) | 2004-05-19 | 2005-05-19 | Anvendelse af natriumdeoxycholat til ikke-kirurgisk fjernelse af fedt |
Country Status (25)
Country | Link |
---|---|
US (3) | US7622130B2 (da) |
EP (8) | EP2422789B1 (da) |
JP (2) | JP5060295B2 (da) |
KR (1) | KR101217497B1 (da) |
CN (2) | CN105233287A (da) |
AT (2) | ATE521355T1 (da) |
AU (1) | AU2005245002B8 (da) |
CA (1) | CA2567298C (da) |
CY (4) | CY1111974T1 (da) |
DK (5) | DK2422789T3 (da) |
ES (5) | ES2372499T3 (da) |
FI (1) | FI3692995T3 (da) |
FR (2) | FR20C1048I2 (da) |
HK (2) | HK1099521A1 (da) |
HU (5) | HUE038247T2 (da) |
IL (2) | IL179008A (da) |
LT (3) | LT2422789T (da) |
MX (1) | MXPA06013437A (da) |
NL (1) | NL301229I2 (da) |
NZ (2) | NZ586818A (da) |
PL (4) | PL1758590T3 (da) |
PT (5) | PT2422789T (da) |
SI (4) | SI2422789T1 (da) |
TR (1) | TR201802446T4 (da) |
WO (2) | WO2005117900A1 (da) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2422789B1 (en) * | 2004-05-19 | 2017-11-22 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Injectable coposition comprising sodium deoxycholate |
US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
US20060074057A1 (en) * | 2004-10-04 | 2006-04-06 | Eric Marchewitz | Use of chenodeoxycholic acid for reducing adipose tissue |
JP4646669B2 (ja) * | 2005-03-30 | 2011-03-09 | キヤノン株式会社 | 吐出用液体、吐出方法、液滴化方法、カートリッジ及び吐出装置 |
US20060222695A1 (en) * | 2005-04-01 | 2006-10-05 | Filiberto Zadini | Deoxycholic acid liposome-based dermatological topical preparation |
US20070071706A1 (en) * | 2005-09-28 | 2007-03-29 | Filiberto Zadini | Lipodissolving dermatological topical preparation |
US7676604B2 (en) * | 2005-11-22 | 2010-03-09 | Intel Corporation | Task context direct indexing in a protocol engine |
US8304383B2 (en) | 2005-11-22 | 2012-11-06 | Atheronova Operations, Inc. | Dissolution of arterial plaque |
US20090035348A1 (en) * | 2005-11-22 | 2009-02-05 | Z & Z Medical Holdings, Inc. | Dissolution of arterial plaque |
US20110082124A1 (en) * | 2006-02-23 | 2011-04-07 | Kythera Biopharmaceuticals, Inc. | Detergent compositions for treatment of lipomas and other conditions |
WO2008008468A2 (en) * | 2006-07-14 | 2008-01-17 | Duncan Diane I | Compositions and methods for fat reduction |
US20100063006A1 (en) * | 2006-11-22 | 2010-03-11 | American Network Of Lipolysis, Llc | Compositions and methods to reduce fat and retract skin |
DE102007015701A1 (de) * | 2007-03-19 | 2008-09-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung |
US8057381B2 (en) * | 2007-04-16 | 2011-11-15 | Allen Iii William F | Method and implant material for treatment of urinary incontinence |
JOP20180077A1 (ar) * | 2007-06-19 | 2019-01-30 | Kythera Biopharmaceuticals Inc | تركيبات وطرق لحمض صفراوي تخليقي |
AU2008265721B2 (en) * | 2007-06-19 | 2014-03-20 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid composition, method, and preparation |
US8242294B2 (en) | 2007-06-19 | 2012-08-14 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
US20080318870A1 (en) | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
US7943187B2 (en) | 2008-05-23 | 2011-05-17 | Bakr Rabie | Paeoniflorin preparations and uses thereof for fat reduction |
FR2937554B1 (fr) * | 2008-10-27 | 2010-11-12 | Yves Crassas | Solutions salines aqueuses pour la destruction de tissus graisseux |
KR20120104487A (ko) * | 2009-03-02 | 2012-09-21 | 도리스 헥스셀 | 의료용 미용 지방수축 |
US10213441B2 (en) | 2009-03-02 | 2019-02-26 | Doris Hexsel | Medicinal cosmetic lipoatrophy |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
EP2485738A4 (en) * | 2009-10-09 | 2015-04-01 | Atheronova Operations Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF ADIPOSITAS |
GB2480632A (en) | 2010-05-25 | 2011-11-30 | Kythera Biopharmaceuticals Inc | Preparation of 12-keto and 12-alpha-hydroxy steroids |
CA2783017C (en) | 2010-08-12 | 2018-05-15 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
MX363465B (es) | 2011-02-18 | 2019-03-25 | Kythera Biopharmaceuticals Inc | Tratamiento de la grasa submental. |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
TWI572616B (zh) | 2011-06-16 | 2017-03-01 | 凱瑟拉生物製藥有限公司 | 去氧膽酸之組成物及用途及其相關方法 |
EA034320B1 (ru) * | 2011-08-23 | 2020-01-28 | Китера Биофармасьютикалз, Инк. | Композиции дезоксихолата натрия |
NZ620040A (en) * | 2011-08-23 | 2016-06-24 | Kythera Biopharmaceuticals Inc | Formulations of deoxycholic acid and salts thereof |
EP2735310B1 (en) | 2011-08-23 | 2017-10-11 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
FI3581199T3 (fi) * | 2011-10-21 | 2023-08-18 | Endo Global Ventures | Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
WO2013093947A1 (en) * | 2011-12-21 | 2013-06-27 | Motolese Pasquale | Cosmetic composition and uses thereof in the treatment of lipodystrophies |
ES2904884T3 (es) | 2012-01-12 | 2022-04-06 | Endo Global Ventures | Enzima del clostridium histolyticum |
US20150313825A1 (en) | 2012-11-21 | 2015-11-05 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
NO2753788T3 (da) | 2013-05-10 | 2018-06-16 | ||
WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
WO2015179282A1 (en) | 2014-05-20 | 2015-11-26 | Topokine Therapeutics, Inc. | Topical compositions comprising a thiazolidinedione |
EP3148549A4 (en) * | 2014-06-01 | 2017-11-15 | Galmed Research and Development Ltd. | Fatty acid bile acid conjugates for treatment of lipodystrophy |
CN114224829A (zh) | 2014-06-27 | 2022-03-25 | 玫帝托克斯股份有限公司 | 用于减少脂肪的胆酸类与盐类的制剂及用途 |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
CA2972065A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
EP3355882A1 (en) * | 2015-10-01 | 2018-08-08 | Kythera Biopharmaceuticals, Inc. | Compositions comprising a statin for use in methods of adipolysis |
JP2018532806A (ja) * | 2015-11-04 | 2018-11-08 | キセラ バイオファーマシューティカルズ インコーポレイテッド | デオキシコール酸およびその塩による蓄積脂肪の処置方法 |
JP6219430B2 (ja) * | 2016-03-18 | 2017-10-25 | キテラ バイオファーマシューティカルズ,インコーポレイテッド | デオキシコール酸およびその塩類の製剤 |
WO2017211820A1 (en) | 2016-06-06 | 2017-12-14 | Bionice, S.L.U. | Methods for the preparation of deoxycholic acid, and intermediates useful in the preparation of deoxycholic acid |
US20180078621A1 (en) * | 2016-09-22 | 2018-03-22 | Kyoung Lack Lee | Composition for hypotonic lipolysis and manufacturing method thereof |
KR101841193B1 (ko) * | 2016-09-22 | 2018-03-22 | 이경락 | 저장성 지방 분해 조성물 및 그의 제조 방법 |
BR112019018277A2 (pt) | 2017-03-01 | 2020-06-30 | Endo Ventures Limited | aparelho e método para avaliar e tratar celulite |
CN118325876A (zh) | 2017-03-28 | 2024-07-12 | 恩多风投有限公司 | 生产胶原酶的改进方法 |
AU2018256263B2 (en) * | 2017-04-21 | 2021-05-06 | Ami Pharm Co., Ltd. | Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same |
KR102093872B1 (ko) * | 2017-07-03 | 2020-03-27 | 진호성 | 지방제거용 주사제 조성물 및 이의 제조방법 |
JP6937893B2 (ja) * | 2017-08-03 | 2021-09-22 | メディトックス インク. | 胆汁酸類を製造するための方法 |
JP6356329B2 (ja) * | 2017-09-27 | 2018-07-11 | キテラ バイオファーマシューティカルズ,インコーポレイテッド | デオキシコール酸およびその塩類の製剤 |
CN111511755A (zh) | 2017-10-24 | 2020-08-07 | 比奥尼斯有限责任公司 | 脱氧胆酸的制备 |
CN110302082A (zh) * | 2018-03-27 | 2019-10-08 | 上海同柏生物科技有限公司 | 用于减少身体脂肪沉积的技术及组合物制剂与应用 |
JP6594486B2 (ja) * | 2018-06-13 | 2019-10-23 | キテラ バイオファーマシューティカルズ,インコーポレイテッド | デオキシコール酸およびその塩類の製剤 |
KR102116238B1 (ko) * | 2018-08-28 | 2020-05-28 | 이경락 | 저장성 지방 분해 조성물 및 그의 제조 방법 |
WO2020081590A1 (en) | 2018-10-16 | 2020-04-23 | Rotunda Adam M | Alcohol-based compositions and uses thereof |
US11439659B2 (en) * | 2018-12-03 | 2022-09-13 | The Regents Of The University Of California | Methods and compositions to prevent and treat inflammation and allergic reactions |
KR102172439B1 (ko) * | 2018-12-05 | 2020-10-30 | 송미희 | 지방 분해용 조성물 및 이를 포함하는 주사제 조성물 |
KR102064864B1 (ko) | 2019-02-08 | 2020-01-10 | (주)제테마 | 국소 주사용 조성물 |
KR102111346B1 (ko) | 2019-08-20 | 2020-05-22 | 아영창 | 침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물 |
WO2023287261A1 (ko) | 2021-07-16 | 2023-01-19 | 주식회사 스카이테라퓨틱스 | 담즙산 또는 담즙산 염의 분자 회합체를 포함하는 화장료 조성물 |
EP4346837A1 (en) * | 2022-07-05 | 2024-04-10 | Glonova Pharma Co., Ltd. | Injectable composition comprising cytolytic compound in gel, gel-forming solution or gel-forming suspension for reduction of fat |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4113882A (en) * | 1974-10-21 | 1978-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Stabilized oral prostaglandin formulation and the process for the preparation thereof |
IT1202370B (it) * | 1976-07-12 | 1989-02-09 | Hoffmann La Roche | Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti |
US4117121A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
IT8167097A0 (it) * | 1981-01-26 | 1981-01-26 | Unilever Nv | Composizione cosmetica per il trattamento della pelle o dei capelli |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
GB8417895D0 (en) | 1984-07-13 | 1984-08-15 | Marples B A | Pharmaceutical anti-fungal composition |
JPS61158995A (ja) * | 1984-12-28 | 1986-07-18 | Takara Shironaga | 脂肪肝,胆石,胃粘膜障害発生の予防薬または治療薬 |
US4866044A (en) * | 1985-07-09 | 1989-09-12 | Takeda Chemical Industries, Ltd. | Solubilized composition of poorly-soluble pharmaceutical product |
IT1213453B (it) * | 1985-08-02 | 1989-12-20 | Merz & Co Gmbh & Co | Composizione farmaceutica. |
US5326562A (en) * | 1986-06-03 | 1994-07-05 | Incyte Pharmaceuticals, Inc. | Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I |
US4952411A (en) | 1987-02-25 | 1990-08-28 | Trustees Of Columbia University In The City Of New York | Method of inhibiting the transmission of AIDS virus |
US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
IL89530A0 (en) * | 1989-03-08 | 1989-09-10 | Jeffrey J Feigenbaum | Compositions containing forskolin |
GB8909022D0 (en) | 1989-04-20 | 1989-06-07 | Cortecs Ltd | Pharmaceutical compositions |
EP0408174A1 (en) | 1989-07-12 | 1991-01-16 | Warner-Lambert Company | Antiseptic composition containing hexahydro-5-pyrimidinamine compounds |
AU6461090A (en) | 1989-10-30 | 1991-05-02 | Abbott Laboratories | Injectable formulation for lipophilic drugs |
US5085864A (en) * | 1989-10-30 | 1992-02-04 | Abbott Laboratories | Injectable formulation for lipophilic drugs |
CA2033725C (en) | 1990-01-24 | 2001-05-29 | Folker Pittrof | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
US6120805A (en) * | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
JP3032315B2 (ja) * | 1991-01-14 | 2000-04-17 | 健二 片桐 | 脂肪肝治療剤 |
GB9212511D0 (en) * | 1992-06-12 | 1992-07-22 | Cortecs Ltd | Pharmaceutical compositions |
US5674855A (en) | 1992-08-12 | 1997-10-07 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
US5344822A (en) | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
US6663885B1 (en) * | 1993-03-15 | 2003-12-16 | A. Natterman & Cie Gmbh | Aqueous liposome system and a method for the preparation of such a liposome system |
GB9320597D0 (en) | 1993-10-06 | 1993-11-24 | Proteus Molecular Design | Improvements in and realting to vaccines |
US5395545A (en) * | 1993-10-21 | 1995-03-07 | Akzo N.V. | Cleaning solution for automated analyzers |
MY131733A (en) | 1994-12-22 | 2007-08-30 | Astra Ab | Aerosol drug formulations |
JP2740153B2 (ja) | 1995-03-07 | 1998-04-15 | エフ・ホフマン−ラ ロシユ アーゲー | 混合ミセル |
US5616342A (en) | 1995-04-11 | 1997-04-01 | Pdt, Inc. | Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof |
US5759445A (en) | 1995-05-24 | 1998-06-02 | Matsushita Electric Industrial Co., Ltd. | Lipid-dispersed solution and process for producing the same |
US20040101569A1 (en) | 1996-05-16 | 2004-05-27 | Lorus Therapeutics Inc. | Immunomodulating compositions from bile |
IL127955A0 (en) | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
US5952392A (en) * | 1996-09-17 | 1999-09-14 | Avanir Pharmaceuticals | Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition |
US7351421B2 (en) | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
CA2282411A1 (en) | 1997-02-27 | 1998-09-03 | Nippon Shinyaku Co., Ltd. | Fat emulsion for oral administration |
US5891083A (en) | 1997-04-22 | 1999-04-06 | Capella; Rafael F. | Suction lipolysis |
US20020107291A1 (en) | 1997-05-26 | 2002-08-08 | Vincenzo De Tommaso | Clear, injectable formulation of an anesthetic compound |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
CA2294334A1 (en) | 1997-06-13 | 1998-12-17 | Adi Eisenberg | Compositions for delivery of biological agents and methods for the preparation thereof |
US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
US6054421A (en) * | 1997-09-23 | 2000-04-25 | Scimed Life Systems, Inc. | Medical emulsion lubricant |
US6281175B1 (en) * | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
US6221378B1 (en) * | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
US6350458B1 (en) * | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US7303768B2 (en) | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US20050158408A1 (en) | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
RU2224523C2 (ru) * | 1998-07-24 | 2004-02-27 | Сео Хонг Ю | Водный раствор, содержащий желчную кислоту, и способ его получения |
TW570805B (en) * | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
SE9803240D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
US6417179B1 (en) | 1998-10-13 | 2002-07-09 | Craig G. Burkhart | Ear wax solution |
US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
EP1156782B1 (en) | 1999-03-03 | 2005-05-04 | Eli Lilly And Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
US6350432B1 (en) * | 1999-03-19 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Pressurized container having an aerosolized pharmaceutical composition |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6489312B1 (en) * | 1999-06-15 | 2002-12-03 | Medimmune Oncology, Inc. | Pharmaceutical formulations comprising aminoalkyl phosphorothioates |
US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
WO2001056547A2 (en) * | 2000-02-04 | 2001-08-09 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
GB0009773D0 (en) * | 2000-04-19 | 2000-06-07 | Univ Cardiff | Particulate composition |
FR2813189B1 (fr) | 2000-08-31 | 2003-02-28 | Oreal | Creme cosmetique moussante pour le traitement des peaux grasses |
CA2422178A1 (en) * | 2000-09-08 | 2002-03-14 | Dow Global Technologies Inc. | Sequential detection ion chromatography |
EP1609468A3 (en) | 2000-11-22 | 2006-01-25 | Rxkinetix, Inc. | A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis |
CA2445091A1 (en) * | 2000-12-13 | 2002-06-20 | Janos Feher | Pharmaceutical compositions for treatment of digestive disorders and associated diseases |
US6607784B2 (en) * | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
EP1367970A1 (en) * | 2001-01-24 | 2003-12-10 | Summanus Pharma, Inc. | Alkyl aryl polyether alcohol polymers for improvement of nasal breathing |
SE0100901D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | New composition |
DK1389089T3 (da) | 2001-03-27 | 2009-12-21 | Phares Pharm Res Nv | Fremgangsmådeog sammensætning til solubilisering af en biologisk aktiv forbindelse med lav vandoplöselighed |
CA2446060A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
EP2591806A1 (en) | 2001-06-14 | 2013-05-15 | Otsuka Pharmaceutical Co., Ltd. | Medicinal composition |
US20030083286A1 (en) | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
US6713470B2 (en) * | 2002-01-22 | 2004-03-30 | Ml Laboratories Plc | Method of treatment |
GB0207529D0 (en) | 2002-04-02 | 2002-05-08 | Norbrook Lab Ltd | Injectable veterinary composition for small animals |
EP1503737B1 (en) | 2002-05-06 | 2009-01-07 | Elan Pharma International Limited | Nanoparticulate nystatin formulations |
JP2005531570A (ja) * | 2002-05-23 | 2005-10-20 | ユーエムディー, インコーポレイテッド | 貫粘膜薬物送達及び凍結保護のための組成物及び方法 |
US20040220283A1 (en) * | 2002-07-29 | 2004-11-04 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
NZ538255A (en) | 2002-07-29 | 2006-11-30 | Transform Pharmaceuticals Inc | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
US20050163821A1 (en) | 2002-08-02 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting Biodegradable Stent and Delivery Means |
US20050019404A1 (en) | 2003-06-30 | 2005-01-27 | Hsing-Wen Sung | Drug-eluting biodegradable stent |
KR100482269B1 (ko) * | 2002-10-08 | 2005-04-14 | 센츄론(주) | 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법 |
EP1555976A4 (en) | 2002-10-29 | 2007-11-14 | Transform Pharmaceuticals Inc | PROPOFOL ASSOCIATED WITH CYSTEINE |
US20050079228A1 (en) * | 2003-05-30 | 2005-04-14 | Ashish Jaiswal | Clear, stable topical compositions of clarithromycin and processes for their preparation |
US7342011B2 (en) | 2003-08-22 | 2008-03-11 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
DE10349979B4 (de) * | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
US20050089555A1 (en) * | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
CA2550647A1 (en) * | 2003-12-22 | 2005-07-14 | Aventis Pharmaceuticals Inc. | Injectable phosphatidylcholine preparations |
US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
DE10361067A1 (de) * | 2003-12-22 | 2005-07-14 | Aventis Pharma Deutschland Gmbh | Medikamentöse Lipolyse von Fettansammlungen |
KR100638041B1 (ko) | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
EP2422789B1 (en) * | 2004-05-19 | 2017-11-22 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Injectable coposition comprising sodium deoxycholate |
US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
FR2870741B1 (fr) | 2004-05-25 | 2008-03-14 | Coletica Sa | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
CN1960707B (zh) | 2004-06-03 | 2012-11-14 | 博莱科瑞士股份有限公司 | 用于治疗和/或诊断用途的脂质集合体 |
US20050287199A1 (en) | 2004-06-28 | 2005-12-29 | Teresa Ann Denney | Therapeutic micro nutrient composition for lipolysis and drug delivery |
WO2006007675A1 (en) * | 2004-07-20 | 2006-01-26 | Libbs Farmacêutica Ltda. | Cholic acid and/or its derivatives for the reduction of localized fat in the human body |
US20060074057A1 (en) * | 2004-10-04 | 2006-04-06 | Eric Marchewitz | Use of chenodeoxycholic acid for reducing adipose tissue |
US20060222695A1 (en) * | 2005-04-01 | 2006-10-05 | Filiberto Zadini | Deoxycholic acid liposome-based dermatological topical preparation |
-
2005
- 2005-02-08 EP EP11166225.0A patent/EP2422789B1/en active Active
- 2005-02-08 EP EP18185014.0A patent/EP3424508B1/en active Active
- 2005-02-08 PT PT111662250T patent/PT2422789T/pt unknown
- 2005-02-08 DK DK11166225.0T patent/DK2422789T3/da active
- 2005-02-08 PL PL05722895T patent/PL1758590T3/pl unknown
- 2005-02-08 SI SI200532194T patent/SI2422789T1/en unknown
- 2005-02-08 PT PT05722895T patent/PT1758590E/pt unknown
- 2005-02-08 EP EP05722895A patent/EP1758590B1/en active Active
- 2005-02-08 EP EP12189943A patent/EP2550968A1/en not_active Withdrawn
- 2005-02-08 PL PL11166225T patent/PL2422789T3/pl unknown
- 2005-02-08 SI SI200531417T patent/SI1758590T1/sl unknown
- 2005-02-08 ES ES05722895T patent/ES2372499T3/es active Active
- 2005-02-08 HU HUE11166225A patent/HUE038247T2/hu unknown
- 2005-02-08 AT AT05722895T patent/ATE521355T1/de active
- 2005-02-08 WO PCT/US2005/004184 patent/WO2005117900A1/en active Application Filing
- 2005-02-08 LT LTEP11166225.0T patent/LT2422789T/lt unknown
- 2005-02-08 ES ES11166225.0T patent/ES2660172T3/es active Active
- 2005-02-08 US US11/054,171 patent/US7622130B2/en active Active
- 2005-02-08 TR TR2018/02446T patent/TR201802446T4/tr unknown
- 2005-02-08 DK DK05722895.9T patent/DK1758590T3/da active
- 2005-02-08 MX MXPA06013437A patent/MXPA06013437A/es active IP Right Grant
- 2005-05-19 PL PL05751896T patent/PL1748780T3/pl unknown
- 2005-05-19 ES ES11166230T patent/ES2795749T3/es active Active
- 2005-05-19 EP EP05751896A patent/EP1748780B1/en active Active
- 2005-05-19 NZ NZ586818A patent/NZ586818A/xx unknown
- 2005-05-19 NZ NZ551000A patent/NZ551000A/en unknown
- 2005-05-19 KR KR1020067023922A patent/KR101217497B1/ko active IP Right Review Request
- 2005-05-19 FI FIEP20166727.6T patent/FI3692995T3/fi active
- 2005-05-19 PT PT05751896T patent/PT1748780E/pt unknown
- 2005-05-19 SI SI200532276T patent/SI2380576T1/sl unknown
- 2005-05-19 CN CN201510621591.9A patent/CN105233287A/zh active Pending
- 2005-05-19 WO PCT/US2005/017957 patent/WO2005112942A1/en active Application Filing
- 2005-05-19 AT AT05751896T patent/ATE518565T1/de active
- 2005-05-19 EP EP20166727.6A patent/EP3692995B1/en active Active
- 2005-05-19 CA CA2567298A patent/CA2567298C/en active Active
- 2005-05-19 DK DK05751896.1T patent/DK1748780T3/da active
- 2005-05-19 HU HUE11166230A patent/HUE049990T2/hu unknown
- 2005-05-19 ES ES05751896T patent/ES2372416T3/es active Active
- 2005-05-19 DK DK20166727.6T patent/DK3692995T3/da active
- 2005-05-19 AU AU2005245002A patent/AU2005245002B8/en active Active
- 2005-05-19 PT PT111662300T patent/PT2380576T/pt unknown
- 2005-05-19 ES ES20166727T patent/ES2939383T3/es active Active
- 2005-05-19 JP JP2007527519A patent/JP5060295B2/ja active Active
- 2005-05-19 DK DK11166230.0T patent/DK2380576T3/da active
- 2005-05-19 PL PL20166727.6T patent/PL3692995T3/pl unknown
- 2005-05-19 EP EP11166230.0A patent/EP2380576B1/en active Active
- 2005-05-19 HU HUE20166727A patent/HUE061343T2/hu unknown
- 2005-05-19 LT LTEP11166230.0T patent/LT2380576T/lt unknown
- 2005-05-19 SI SI200531400T patent/SI1748780T1/sl unknown
- 2005-05-19 PT PT201667276T patent/PT3692995T/pt unknown
- 2005-05-19 EP EP12189947A patent/EP2572718A1/en not_active Withdrawn
- 2005-05-19 CN CN200580015906.XA patent/CN101018553B/zh active Active
-
2006
- 2006-03-13 US US11/375,173 patent/US20060154906A1/en not_active Abandoned
- 2006-11-02 IL IL179008A patent/IL179008A/en unknown
-
2007
- 2007-06-27 HK HK07106866.1A patent/HK1099521A1/xx unknown
- 2007-08-14 HK HK07108856.9A patent/HK1101062A1/xx unknown
-
2009
- 2009-10-28 US US12/607,882 patent/US8298556B2/en active Active
-
2010
- 2010-07-21 IL IL207126A patent/IL207126A/en active IP Right Grant
-
2011
- 2011-10-25 CY CY20111101007T patent/CY1111974T1/el unknown
- 2011-10-31 CY CY20111101044T patent/CY1112204T1/el unknown
-
2012
- 2012-05-07 JP JP2012105708A patent/JP2012176966A/ja active Pending
-
2017
- 2017-01-23 HU HUS1700004C patent/HUS1700004I1/hu unknown
- 2017-03-08 LT LTPA2017006C patent/LTPA2017006I1/lt unknown
-
2018
- 2018-02-21 CY CY20181100197T patent/CY1120146T1/el unknown
- 2018-03-13 CY CY2018008C patent/CY2018008I1/el unknown
-
2020
- 2020-10-07 FR FR20C1048C patent/FR20C1048I2/fr active Active
-
2023
- 2023-04-26 HU HUS2300016C patent/HUS2300016I1/hu unknown
- 2023-04-26 NL NL301229C patent/NL301229I2/nl unknown
- 2023-04-28 FR FR23C1018C patent/FR23C1018I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2422789T3 (da) | Injicerbar sammensætning omfattende natriumdeoxycholat | |
US7754230B2 (en) | Methods and related compositions for reduction of fat | |
Rotunda et al. | Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution | |
US20140004206A1 (en) | Methods and related compositions for reduction of fat and skin tightening | |
ES2739453T3 (es) | Métodos y composiciones relacionadas para la reducción de grasa y el estiramiento de la piel | |
AU2011204874A1 (en) | Methods and related compositions for reduction of fat |